Catalyst Pharmaceuticals
1D
1W
1M
3M
1Y
5Y
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CPRX and other ETFs, options, and stocks.About CPRX
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E.
CEOPatrick J. McEnany
CEOPatrick J. McEnany
Employees76
Employees76
HeadquartersCoral Gables, Florida
HeadquartersCoral Gables, Florida
Founded2002
Founded2002
Employees76
Employees76
CPRX Key Statistics
Market cap1.77B
Market cap1.77B
Price-Earnings ratio27.92
Price-Earnings ratio27.92
Dividend yield—
Dividend yield—
Average volume2.98M
Average volume2.98M
High today$17.20
High today$17.20
Low today$16.47
Low today$16.47
Open price$16.93
Open price$16.93
Volume1.01M
Volume1.01M
52 Week high$17.76
52 Week high$17.76
52 Week low$5.24
52 Week low$5.24
CPRX News
Benzinga 4d
VP At This Health Care Company Sells $1.98M of Stock - Catalyst Pharmaceuticals - BenzingaAlicia Grande, VP at Catalyst Pharmaceuticals CPRX, reported a large insider sell on November 23, according to a new SEC filing. What Happened: A Form 4 filing...
Investor's Business Daily 7d
IBD Stock Of The Day Catalyst Pharma Is Hinting At An Acquisition — Why The Timing Is PerfectCatalyst Pharmaceuticals Catalyst Pharmaceuticals CPRX $ 15.24 $0.36 2.28% 40% IBD Stock Analysis Catalyst Pharma stock is in cup-with-handle base with 16.76 bu...
CPRX Earnings
$0.00
$0.09
$0.19
$0.28
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Estimated— per share
Estimated— per share
ActualExpected Mar 15, After Hours
ActualExpected Mar 15, After Hours